BUY ONLINE
WHERE TO BUY 
Promensil® NEWSLETTER
CONTACT US
Clinical News
SOGC Announces Promensil Licenses in its February 2011 Newsletter (page 9) |
|
Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts |
|
Red Clover isoflavones are safe and well tolerated in women with a family history of breast cancer |
|
Meta-Analysis Supports use of Red Clover Isoflavones for Treating Symptoms of Menopause |
|
New guidelines confirm role for natural approach to menopause symptoms |
|
Pharmacology comes to Phytoestrogens |
SOGC Announces Promensil Licenses in its February 2011 Newsletter (page 9)
Promensil approved by Health Canada
Natural Product Numbers (NPN) have been issued to Promensil by the Natural Health Products Directorate, supporting Promensil's claims of efficacy, safety and quality for the treatment of menopause symptoms.
Promensil is a standardized formulation of four key isoflavones (genistein, daidzein, formononetin and biochanin A) extracted from red clover. The use of Promensil's red clover isoflavones was validated as a complementary therapy for treatment of menopausal patients in the article "Complementary and Hormonal Therapy for Vasomotor Symptom Relief: A Conservative Clinical Approach" by L. Nachtigall et al., published in the JOGC April 2006 (p 279-289).
Promensil is sold over the counter in most pharmacies in a 40 mg tablet (NPN 80015467), a double strength product in an 80 mg tablet (NPN 80016071), and as Promensil Vitality with 40 mg of isoflavones plus 500 mg of elemental calcium and 140 IU of vitamin D3 (NPN 80016069).
Further information and clinical studies can be found at www.promensil.ca under "Healthcare Professionals". A "Promensil Clinical Summary" is also available online or by requesting a printed copy in English or French by email at jamie.hanna@novogen.com.
Click here to download the entire SOGC February 2011 Newsletter
Back to TopRed Clover isoflavones are safe and well tolerated in women with a family history of breast cancer
This study 59 conducted by Trevor Powles et al of Parkside Oncology Unit, London, supports the growing body of evidence that treatment with red clover isoflavones is safe and well tolerated in healthy women. This 3 year, randomized, double blind, placebo controlled trial studied the effects of red clover isoflavones on women with at least one first degree relative with breast cancer.
"Red clover isoflavones are safe, well tolerated and show no evidence of an estrogenic effect on breast density when taken for three years by women with a first degree relative with breast cancer." Extract from paper.
"The lack of stimulatory effect found in this study (the longest to date) is encouraging and supports the tolerability of red clover isoflavones based on epidemiological and tissue selectivity data." Extract from paper.
Meta-Analysis Supports use of Red Clover Isoflavones for Treating Symptoms of Menopause
The study, published on an early online version of Maturitas 53 - The European Menopause Journal, involved a systematic review and meta-analysis of all (17) randomised, controlled trials of isoflavone supplementation to determine the efficacy of isoflavone therapy in reducing the number of daily menopausal flushes.
"Overall, isoflavone therapy was associated with about a 30% reduction in the number of flushes, but the effect was greater in women with frequent flushes," said Professor Howes.
"The study adds substantial evidence to the benefits of using red clover isoflavones to reduce the number of hot flushes associated with menopause. There has clearly been some scepticism among Australian healthcare professionals about red clover isoflavones but this has largely been because of the inadequate design of many individual studies," said Professor Howes.
New guidelines confirm role for natural approach to menopause symptoms
Dr Rod Baber from Royal North Shore Hospital in Sydney, who developed the algorithm with Dr Lila Nachtigall, Professor of Obstetrics & Gynaecology at the New York University School of Medicine, and six other leading specialists from Canada, United Kingdom, USA and The Netherlands, said the algorithm provides a tool that is helpful for menopausal patients and those treating them.54
"The development of the algorithm responds to a genuine need from GP's for guidance about the use of menopause treatments other than hormone therapy."
Pharmacology comes to Phytoestrogens
Three speakers presented new information about red clover isoflavones at the recent 11th World Congress on the Menopause, in Buenos Aires, Argentina, in a symposium titled "Pharmacology comes to Phytoestrogens".
The congress is organised by the International Menopause Society, and attended by gynaecologists, general practitioners, nurse practitioners and academics in the field of menopause.
Dr Stephen Barnes, Professor of Pharmacology and Toxicology at the University of Alabama at Birmingham presented on the biology and actions of isoflavones.
Dr Lila Nachtigall, Professor of Obstetrics and Gynecology at the Department of Obstetrics and Gynecology New York University School of Medicine presented on the clinical actions of isoflavones. Using an algorithm Dr Nachtigall illustrated when isoflavones are an appropriate treatment option for menopause symptoms.
Professor Alan Husband, group director of research for Novogen presented on the drug development programme resulting from isoflavone research, including phenoxodiol, a compound currently in human clinical trials in patients with ovarian and prostate cancer.
Download the Abstracts from the Symposium
